Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + sintilimab + SIRT
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intra-arterial
01
Overview
Lenvatinib + sintilimab + SIRT is a combination therapy consisting of lenvatinib, a multi-kinase inhibitor; sintilimab, an anti-PD-1 monoclonal antibody; and selective internal radiation therapy (SIRT), also known as radioembolization. Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation. Sintilimab blocks the PD-1 pathway to enhance anti-tumor immune responses. SIRT delivers targeted internal radiation directly to liver tumors via microspheres loaded with radioactive isotopes, typically yttrium-90. This triple regimen is under investigation for advanced hepatocellular carcinoma (HCC) and other liver cancers, aiming to leverage synergistic effects of targeted therapy, immunotherapy, and locoregional radiotherapy.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + sintilimab + SIRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + sintilimab + SIRT.